Daewoong Pharmaceutical announced on June 5 the official launch of its high-purity botulinum toxin, Nabotah, in Qatar, marking the product’s entry into its third Gulf market following Saudi Arabia and the UAE.
A launch event held in Doha at the St. Regis Hotel on May 30 drew around 200 local medical professionals. The symposium showcased Nabotah’s advanced features and Nabo-Lift, a proprietary technique developed by Daewoong that uses micro-injections for facial lifting, wrinkle reduction, and collagen stimulation.
With a per capita GDP of nearly $80,000, Qatar represents a high-potential market in the Middle East and North Africa (MENA) region, where demand for premium aesthetic procedures is on the rise. The region’s shared cultural and linguistic ties further support market expansion.
Nabotah’s expansion into Qatar signals Daewoong’s broader regional strategy. According to Yoon Jun-soo, Head of the Nabotah Business Division, “The addition of Qatar as a strategic base strengthens our presence in the Middle East. We will continue growing through our competitive product quality and differentiated techniques like Nabo-Lift.”
Moving forward, Daewoong plans to boost brand recognition through localized campaigns and deepen collaborations with regional partners in Qatar and the UAE.
Source: biz.chosun.com
